October 20, 2020 • WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs®) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

WindMIL Therapeutics today announced that data regarding MILs® as a potential cancer immunotherapy for hematological and solid tumors has been selected for a poster presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting which will take place virtually November 9 – 14, 2020.

October 13, 2020 • WindMIL Therapeutics and Stephenson Cancer Center Announce Collaboration to Collect Bone Marrow from Patients with Renal and Urothelial Carcinomas to Develop Marrow Infiltrating Lymphocytes (MILs®)

WindMIL Therapeutics and Stephenson Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with renal (RCC) and urothelial carcinomas (UC). The study will evaluate generating marrow infiltrating lymphocytes (MILs®) for these patients through WindMIL’s proprietary cellular activation and expansion process. The […]

October 5, 2020 • WindMIL Therapeutics to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

WindMIL Therapeutics today announced that Chairman and Chief Executive Officer Don Hayden will present at the annual Cell & Gene Meeting on the Mesa to be held virtually Monday, October 12 – Friday, October 16, 2020. Company presentations will be available to view on-demand throughout the entirety of the conference.

September 4, 2020 • WindMIL Therapeutics to Present at Citi’s 15th Annual BioPharma Virtual Conference

WindMIL Therapeutics today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Citi’s 15th Annual BioPharma Virtual Conference on Thursday, September 8, 2020 at 4:05 pm EDT.

May 29, 2020 • ASCO Trial-in-Progress Poster – Phase 2 Study of MILs™ – NSCLC for the Treatment of Patients with NSCLC

WindMIL Therapeutics is proud to highlight a Trial-in-Progress (TiP) poster being presented at the American Society for Clinical Oncology (ASCO) 2020 virtual meeting. The poster summarizes WindMIL Therapeutic’s Phase 2 study of MILs™ – NSCLC for the treatment of patients with NSCLC.

May 28, 2020 • WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ – NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced that the first patient has been dosed in the combination therapy portion of its Phase 2 clinical trial to assess the safety and efficacy of MILs™ – NSCLC in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to, or have relapsed on, an anti-PD-1-containing […]

May 27, 2020 • WindMIL Therapeutics to Present at Jefferies Virtual Healthcare Conference 2020

WindMIL Therapeutics today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 8:00 am EDT.

May 19, 2020 • Company Update Presentation – 2020 UBS Virtual Global Healthcare Conference (Link to archived Webcast)

WindMIL Therapeutic’s Chairman and CEO Don Hayden presented a company update at the 2020 UBS Virtual Global Healthcare Conference on Monday, 18 May 2020.  Recordings of the webcast are available through 17 June 2020 at this link.

May 12, 2020 • WindMIL Therapeutics to Present at UBS Virtual Global Healthcare Conference

WindMIL Therapeutics today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 3:50 pm EDT.  

April 21, 2020 • WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics announced it has begun enrollment in the combination therapy portion of its open-label, multi-center Phase 2a clinical trial to assess the safety and efficacy of MILs in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to, or have relapsed on, an anti-PD-1-containing regimen. In this part […]

March 16, 2020 • BioProcess Insider: Grist for the MIL: CDMO Cognate making cell therapies for WindMIL

WindMIL Therapeutics has upped a contract with Cognate BioServices to make its marrow-infiltrating lymphocyte (MIL) cell therapies

March 10, 2020 • WindMIL Therapeutics and Cognate BioServices Announce Agreement to Expand MILs Manufacturing Capacity

WindMIL Therapeutics and Cognate BioServices, Inc. today announced they have entered an agreement to expand WindMIL’s clinical manufacturing capacity.

March 5, 2020 • WindMIL Therapeutics Appoints Patrick Fabbio as Chief Financial Officer

WindMIL Therapeutics today announced the appointment of Patrick Fabbio as Chief Financial Officer, effective March 30. Mr. Fabbio brings more than 25 years of financial, operational and transactional leadership experience in both publicly traded and privately held life science and pharmaceutical companies to this role. He will lead development and execution of the company’s financial […]

February 26, 2020 • BioCentury Emerging Company Profile – WindMIL: T cell source is key

(article behind paywall)

February 11, 2020 • WindMIL Therapeutics and Providence Cancer Institute Announce Collaboration to Collect Bone Marrow from Patients with Breast Cancer to Develop Marrow-Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics and Providence Cancer Institute today announced that the first patient has been identified in an investigator-sponsored study for the collection of bone marrow from patients with breast cancer. The study will evaluate generating marrow-infiltrating lymphocytes (MILs™) for patients through WindMIL’s proprietary cellular activation and expansion process. The study is being conducted at the […]

February 5, 2020 • WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania

WindMIL Therapeutics today announced a collaborative pre-clinical research partnership with University of Pennsylvania (Penn) to explore novel chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) in hematological and solid tumor model settings. The collaboration will leverage WindMIL’s and Penn’s respective expertise to conduct pre-clinical comparisons of the characteristics and functionality of CAR-T and CAR-MIL products.

January 7, 2020 • WindMIL Therapeutics Announces Expansion of Leadership Team

WindMIL Therapeutics today announced the expansion of its leadership team with the appointment of Karen LaRochelle as Senior Vice President, Corporate & Business Development and the promotion of Patrick Dougherty to Senior Vice President, Strategy, Planning & Operations.

December 19, 2019 • WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced it has entered into a new clinical research collaboration with Bristol-Myers Squibb Company (NYSE:BMY) to evaluate the safety and efficacy of WindMIL Therapeutics’ marrow-infiltrating lymphocytes (MILs™) in combination with Bristol-Myers Squibb’s nivolumab (Opdivo®), a PD-1 immune checkpoint inhibitor, in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who […]

December 11, 2019 • WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced that the first patient has been dosed in a Phase 2a clinical trial to determine the safety and efficacy of MILs alone and in combination with an anti-PD-1 in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to or have relapsed on an anti-PD-1-containing […]

December 9, 2019 • WindMIL Therapeutics to Present Data Demonstrating Superior Efficacy of CAR-T cells using Marrow-Infiltrating Lymphocytes (CAR-MILs™) Compared to Peripheral Blood Lymphocytes at the 61st American Society of Hematology Annual Meeting and Exposition

WindMIL Therapeutics will present new data in a poster presentation on Monday, December 9, 2019, at the 61st American Society of Hematology Annual Meeting and Exposition (ASH), demonstrating that chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) possess superior anti-tumor immunity compared to traditional CAR-T cells engineered using peripheral blood lymphocytes (CAR-PBLs).

November 6, 2019 • WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs™) Data Selected for Poster Presentation at 61st American Society of Hematology Annual Meeting and Exposition

WindMIL Therapeutics announced today that data demonstrating the efficacy of chimeric antigen receptor (CAR) T cells developed using MILs (CAR-MILs) in comparison to peripheral blood lymphocytes has been selected for a poster at 61st American Society of Hematology (ASH) Annual Meeting and Exposition. ASH 2019 will be held December 7-10 at the Orange County Convention Center […]

November 5, 2019 • WindMIL Therapeutics to Present Data Demonstrating Marrow-Infiltrating Lymphocytes’ (MILs™) Superior Functionality Compared to Peripheral Blood Counterparts at 34th Annual Meeting of the Society for Immunotherapy of Cancer

WindMIL Therapeutics will present new data in a poster presentation on Saturday, November 9, 2019, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), demonstrating that chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) are more polyfunctional and produce higher levels of pro-inflammatory chemokines and cytokines associated with antitumor activity than CAR-T cells engineered […]

October 15, 2019 • WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Marrow from Patients with Gliomas to Develop Marrow Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics and the University of California, Irvine (UCI) today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with gliomas. The study will evaluate generating marrow infiltrating lymphocytes (MILs™) for these patients through WindMIL’s proprietary cellular activation and expansion process. The study is […]

September 9, 2019 • WindMIL Therapeutics Appoints Urvashi Patel, PhD, as Vice President of Regulatory & Quality Systems

WindMIL Therapeutics has announced the appointment of Urvashi Patel, PhD, as Vice President of Regulatory and Quality Systems. In this role, Dr. Patel will provide strategic vision and executional leadership for regulatory and quality functions and establish associated operations.

July 9, 2019 • WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics (WindMIL) and the University of Michigan Rogel Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with head and neck squamous cell carcinoma (HNSCC).

June 25, 2019 • WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced today that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 study of MILs as a potential treatment for patients with non-small cell lung cancer (NSCLC) who have progressed on an anti-PD-1 containing […]

April 26, 2019 • Endpoints: Peer Review: Don Hayden commits to CEO role at WindMIL; X4 nabs new CMO Lynne Kelley from Histogenics exile

Since leaving a 25-year career and the president of global pharmaceuticals title at Bristol-Myers Squibb in 2005, Don Hayden has kept himself busy as a consultant and adviser to biopharma companies, sometimes juggling seven or eight board appointments. But after a few months as interim CEO of WindMIL Therapeutics, he’s ready to “substantially pull back” on all those commitments as he transitions to a full-time role.

April 25, 2019 • WindMIL Therapeutics Appoints Donald J. Hayden, Jr., as CEO

WindMIL Therapeutics has announced the appointment of Donald J. Hayden, Jr., as CEO.

April 25, 2019 • Philadelphia Business Journal: Former Bristol-Myers Squibb executive named CEO of immunotherapy company

After spending the past four months as interim CEO of WindMIL Therapeutics, former Bristol-Myers Squibb executive Donald J. Hayden Jr. has accepted the position on a permanent basis.

April 25, 2019 • FierceBiotech: WindMIL Therapeutics interim CEO Hayden steps up to the plate

When Donald Hayden, a 25-year veteran of Bristol-Myers Squibb, joined WindMIL Therapeutics as its executive chairman, he figured he would steer the ship until the company’s board picked a permanent CEO. But as he got to know the company and the marrow-infiltrating lymphocytes from which it takes its name, he “threw his hat into the […]

April 25, 2019 • BioCentury: Management tracks: Canbridge, Averum, WindMIL

Cancer immunotherapy company WindMIL Therapeutics Inc. (Baltimore, Md.) said Chairman and interim CEO Donald Hayden will become the permanent CEO.

April 19, 2019 • FierceBiotech: Chutes & Ladders—Gilman buckles in as Arrakis raises $75M, while Wotton takes over at Obsidian

WindMIL Therapeutics, developers of marrow-infiltrating lymphocytes for cancer, has established new leadership positions, promoting Chief Scientific Officer Kimberly Noonan to executive VP and CSO, and operations VP Patrick Dougherty to VP of planning and operations. Noonan also serves as a scientific co-founder of WindMIL.

April 17, 2019 • WindMIL Therapeutics Announces Promotions to Newly Created Leadership Roles as Part of Continued Growth

WindMIL Therapeutics has announced the promotions of Kimberly Noonan, PhD, MPH, to Executive Vice President and Chief Scientific Officer and Patrick Dougherty to Vice President, Planning and Operations. Noonan previously served as Chief Scientific Officer and Dougherty as Vice President, Operations.

March 29, 2019 • Endpoints: Sunao Manabe takes top job at Daiichi Sankyo in wake of AstraZeneca deal; CAR-T player Celyad promotes Filippo Petti to CEO

WindMIL Therapeutics has tapped Sanjin Zvonić, a seasoned exec who most recently led Progenitor Cell Therapy’s integration into Hitachi, to lead its processes and manufacturing.

March 25, 2019 • WindMIL Therapeutics Appoints Sanjin Zvonić, PhD, as Vice President of Process Science and Manufacturing

WindMIL Therapeutics has announced the appointment of Sanjin Zvonić, PhD, as Vice President of Process Science and Manufacturing.

February 1, 2019 • BioPharm International: TrakCel, WindMIL Therapeutics Partner to Develop Supply Chain Platform

TrakCel—a software developer for cell and gene therapy supply chain tracking and orchestration systems—and WindMIL Therapeutics—a clinical-stage oncology cell therapy company—have formed a partnership to build a custom-configured cellular supply chain tracking and orchestration platform.

December 21, 2018 • Endpoints: Colin Freund takes new CEO job at Modra Pharma; Compass recruits Pfizer, Biogen vets to C-suite

As Johns Hopkins spinout WindMIL Therapeutics opens a new office to consolidate its cell therapy work and attract talent in Philadelphia, two execs are joining the outpost. Monil Shah, chief development officer, comes with a string of roles at Brooklyn ImmunoTherapeutics, Ventrus Biosciences, Celgene, FibroGen, Amgen and others on his resume. New VP of operations […]

December 21, 2018 • BioCentury: MANAGEMENT TRACKS: EVOX NAMES MOSES CHAIRMAN; KAPELLER JOINS GV

Cancer immunotherapy company WindMIL Therapeutics Inc. (Baltimore, Md.) hired Monil Shah as chief development officer, a newly created position. He was COO of Brooklyn ImmunoTherapeutics LLC (New York, N.Y.).

December 20, 2018 • WindMIL Therapeutics Expands Leadership Team and Opens Office in Philadelphia

WindMIL Therapeutics has announced the appointments of Monil Shah, PharmD, MBA, as Chief Development Officer, and Patrick Dougherty as Vice President of Operations. The company also announced it has secured office space in Philadelphia to accommodate its expanding executive, operations and clinical teams.

December 20, 2018 • Philadelphia Business Journal: Baltimore immunotherapy company opens Philadelphia office

WindMil Therapeutics, a clinical-stage cancer immunotherapy company based in Baltimore, has opened a Philadelphia office to accommodate its expanding executive, operations and clinical teams.

December 3, 2018 • WindMIL Therapeutics Announces Preclinical Data Demonstrating Marrow-Infiltrating Lymphocytes’ Potential as CAR-Modified T Cell Therapy Platform

WindMIL Therapeutics yesterday announced preclinical data demonstrating that creating CAR T cells from a MIL resulted in superior antigen-specific killing compared to making them from peripheral blood lymphocytes (PBLs). The preclinical data also show that MILs retain their inherent tumor antigen-specificity and capacity to respond through their endogenous tumor antigen-specific T cell receptors. The data […]

November 29, 2018 • BioCentury: Revving up metabolism at ASH 2018

A dive into the ASH 2018 abstracts highlights cancer metabolism as a top focus.

November 26, 2018 • WindMIL Therapeutics Announces Data on Marrow-Infiltrating Lymphocytes Selected for Poster Presentation at 60th American Society of Hematology Annual Meeting

WindMIL Therapeutics today announced that preclinical data demonstrating MILs’ potential as a robust platform for chimeric-antigen receptor (CAR)-modified T cell therapy have been selected for a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting, to be held December 1-4, 2018, in San Diego, CA.

June 18, 2018 • BioSpace: WindMIL Therapeutics Raises $32.53 Million

WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China company QiMing. There was a Series A round worth $11 million.

June 18, 2018 • Wall Street Journal: Immuno-Oncology Company WindMIL Therapeutics Closes $32.5 Million Series B

WindMIL Therapeutics, a Baltimore-based cancer immunotherapy startup, has completed a $32.5 million Series B round led by Qiming Venture Partners USA.